Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpdated the Italy location from Napoli to Naples (Naples, Italy, 80131) and added Naples, Italy, 80131 as a location. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.3.SummaryDifference0.0%

- Check56 days agoChange Detected- Site revision updated from v3.4.1 to v3.4.2. No study content or user-facing details were changed.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page.SummaryDifference0.0%

- Check71 days agoChange DetectedAdded: Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Deleted: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.SummaryDifference0.2%

- Check86 days agoChange DetectedThe update adds a minor revision label v3.3.4 and removes the previous v3.3.3 label from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.